Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to study enrolment.~* Healthy adult females from Chinese origin and residing in China between and including 26 and 45 years of age at the time of the first vaccination.~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* Healthy subjects as established by medical history and history-directed clinical examination before entering into the study.~* Subjects must not be pregnant. Absence of pregnancy will be verified with a urine pregnancy test before each vaccination.~Subjects must be of non-childbearing potential, i.e., have a current tubal ligation, hysterectomy, ovariectomy, be one year post-menopausal, or if of childbearing potential, they must be abstinent or have practiced adequate contraception for 30 days prior to vaccination, have a negative pregnancy test on the day of vaccination and agree to continue such precautions during the entire treatment period and for 2 months after completion of the vaccination series.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after the first dose of vaccine.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* A subject planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the study period and up to two months after the last vaccine dose.~* Pregnant or breastfeeding subjects must be at least three months post-pregnancy and not breastfeeding to enter the study.~* Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the protocol during the study period.~* Previous administration of 3-O-desacyl-4'-monophosphoryl lipid A or AS04 adjuvant.~* Previous vaccination against hepatitis B or planned administration of any hepatitis B vaccine other than that foreseen by the study protocol during the study period.~* History of hepatitis B infection.~* Known exposure to hepatitis B within the previous 6 weeks.~* History of chronic condition(s) requiring treatment such as cancer or autoimmune disease.~* History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the vaccine (e.g. aluminium).~* Hypersensitivity to latex.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

- Gender: FEMALE
- Minimum Age: 26 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: EXPERIMENTAL): Subjects received a 3-dose vaccination course of the Cervarix™ vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
- Engerix Group (Type: ACTIVE_COMPARATOR): Subjects received a 3-dose vaccination course of the Engerix™-B vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).